Preemptive Analgesia Combination of Celecoxib and Pregabalin in THA

NCT ID: NCT05509946

Last Updated: 2022-08-24

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2/PHASE3

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-10-01

Study Completion Date

2023-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a double-blinded randomized controlled trial aims to evaluate the effect of preemptive analgetic combination of celecoxib and pregabalin to acute pain after total hip arthroplasty. This study will be conducted in Cipto Mangunkusumo Hospital, Jakarta, Indonesia, from October 2022 to April 2023. The subject of this study is adult patient who will be performed total hip arthroplasty.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. Research design This is a double-blind, randomized clinical trial which aimed to evaluate the effect of preemptive analgesia combined with Celecoxib and Pregabalin on acute post-THA pain.
2. Study location This study will be conducted at the Cipto Mangunkusumo Hospital, Jakarta, Indonesia.
3. Study time This study will be conducted in October 2022 - April 2023
4. Population and sample The target population of this study is adult patients undergoing THA surgery. The randomization technique used in this study is a simple randomization technique. Researchers randomly determine the allocation of samples without looking at subjects' status in the population.
5. Inclusion criteria

* Patients \>18 years old
* Patients who come to the RSCM Orthopedic Polyclinic
* Patients undergoing THA surgery
* Patients with Primary and Secondary Pelvic Osteoarthritis
* The patient is taking anti-pain and anti-inflammatory drugs regularly
6. Exclusion criteria

* Patients with mental disorders
* Patients with a history of renal impairment
* Pelvic arthritis patients due to rheumatoid arthritis or infection
* Patients with diabetes and obesity
* Allergy to non-steroidal inflammatory drugs
* Asthma history
* Coagulation disorders
* Patients in the study procedure experienced an incident of severe pain that required another analgesic regimen
* History of hypersensitivity to NSAIDs or sulfonamides

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Arthroplasty Complications Analgetic Celecoxib Pregabalin

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

There are 3 separate groups defined by randomization:

1. single dose of combined celecoxib 400 mg and pregabalin 150 mg an hour before surgery
2. repeated dose of combined celexocib 200 mg twice a day and pregabalin 75 mg twice a day, administered 3 days before surgery
3. placebo administered an hour before surgery
Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Investigators
Randomization performed by simple random sampling, the result is latern given to investigator in an envelope containing codes made by third party outside the research. Investigator and the patient do not know the allocation code

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single dose of celecoxib 400 mg and pregabalin 150 mg

Single dose of celecoxib 400 mg and pregabalin 150 mg administered an hour before surgery

Group Type EXPERIMENTAL

Single dose of celecoxib 400 mg and pregabalin 150 mg

Intervention Type DRUG

Single dose of celecoxib 400 mg and pregabalin 150 mg

Repeated dose of celecoxib 200 mg and pregabalin 75 mg

Repeated dose of celecoxib 200 mg twice a day and pregabalin 75 mg twice a day administered starting from 3 days before surgery

Group Type ACTIVE_COMPARATOR

Repeated dose of celecoxib 200 mg and pregabalin 75 mg

Intervention Type DRUG

Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery

Placebo

Placebo

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Single dose of celecoxib 400 mg and pregabalin 150 mg

Single dose of celecoxib 400 mg and pregabalin 150 mg

Intervention Type DRUG

Repeated dose of celecoxib 200 mg and pregabalin 75 mg

Repeated dose of celecoxib 200 mg and pregabalin 75 mg started 3 days before surgery

Intervention Type DRUG

Placebo

Placebo

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients \>18 years old
2. Patients who come to the RSCM Orthopedic Polyclinic
3. Patients undergoing THA operasi surgery
4. Patients with Primary and Secondary Pelvic Osteoarthritis
5. The patient is taking anti-pain and anti-inflammatory drugs regularly

Exclusion Criteria

1. Patients with mental disorders
2. Patients with a history of renal impairment
3. Pelvic arthritis patients due to rheumatoid arthritis or infection
4. Patients with diabetes and obesity
5. Allergy to non-steroidal inflammatory drugs
6. Asthma history
7. Coagulation disorders
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Indonesia University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Kemas Muhammad Azka Novriandi

Medical doctor, Orthopaedic Surgeon, Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Andri MT Lubis

Role: STUDY_DIRECTOR

Department of Orthopaedic and Traumatology, Faculty of Medicine, Universitas Indonesia

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Kemas MA Novriandi, MD

Role: CONTACT

+628194830011

References

Explore related publications, articles, or registry entries linked to this study.

Sathappan SS, Strauss EJ, Ginat D, Upasani V, Di Cesare PE. Surgical challenges in complex primary total hip arthroplasty. Am J Orthop (Belle Mead NJ). 2007 Oct;36(10):534-41.

Reference Type BACKGROUND
PMID: 18033565 (View on PubMed)

Boisgard S, Descamps S, Bouillet B. Complex primary total hip arthroplasty. Orthop Traumatol Surg Res. 2013 Feb;99(1 Suppl):S34-42. doi: 10.1016/j.otsr.2012.11.008. Epub 2013 Feb 1.

Reference Type BACKGROUND
PMID: 23375960 (View on PubMed)

Ferrata P, Carta S, Fortina M, Scipio D, Riva A, Di Giacinto S. Painful hip arthroplasty: definition. Clin Cases Miner Bone Metab. 2011 May;8(2):19-22.

Reference Type BACKGROUND
PMID: 22461810 (View on PubMed)

Arden NK, Kiran A, Judge A, Biant LC, Javaid MK, Murray DW, Carr AJ, Cooper C, Field RE. What is a good patient reported outcome after total hip replacement? Osteoarthritis Cartilage. 2011 Feb;19(2):155-62. doi: 10.1016/j.joca.2010.10.004. Epub 2010 Oct 15.

Reference Type BACKGROUND
PMID: 20951814 (View on PubMed)

Hayes JH, Cleary R, Gillespie WJ, Pinder IM, Sher JL. Are clinical and patient assessed outcomes affected by reducing length of hospital stay for total hip arthroplasty? J Arthroplasty. 2000 Jun;15(4):448-52. doi: 10.1054/arth.2000.4346.

Reference Type BACKGROUND
PMID: 10884204 (View on PubMed)

Holtzman J, Saleh K, Kane R. Effect of baseline functional status and pain on outcomes of total hip arthroplasty. J Bone Joint Surg Am. 2002 Nov;84(11):1942-8. doi: 10.2106/00004623-200211000-00006.

Reference Type BACKGROUND
PMID: 12429753 (View on PubMed)

Pinto PR, McIntyre T, Araujo-Soares V, Costa P, Ferrero R, Almeida A. A comparison of predictors and intensity of acute postsurgical pain in patients undergoing total hip and knee arthroplasty. J Pain Res. 2017 May 9;10:1087-1098. doi: 10.2147/JPR.S126467. eCollection 2017.

Reference Type BACKGROUND
PMID: 28533697 (View on PubMed)

Singh JA, Noorbaloochi S, Knutson KL. Cytokine and neuropeptide levels are associated with pain relief in patients with chronically painful total knee arthroplasty: a pilot study. BMC Musculoskelet Disord. 2017 Jan 14;18(1):17. doi: 10.1186/s12891-016-1375-2.

Reference Type BACKGROUND
PMID: 28088207 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ID2564

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.